Index

Note: page numbers in italics refer to figures; those in bold to tables.

ABCDE rule, suspicious naevi 100, 101
acute lymphoblastic leukaemia (ALL) 106, 107, 115
acute myeloid leukaemia (AML) 106, 106, 115
adenocarcinoma
colorectal 77
endometrial 85
gastric 75
lung 69
oesophagus 73
ovarian 83
of unknown primary 65
adenomatous polyps, large bowel 77
adjuvant chemotherapy 44–5
adrenocorticotrophic hormone (ACTH), ectopic production 30, 30
adverse effects, treatment 52, 52–3
alcohol consumption 15
alkylating agents 48
aneuploidy 30
 alopecia, treatment-induced 53
alpha-fetoprotein (AFP) 38, 39, 81, 89, 116
AML/ETO fusion gene 107
anaemia 31
angiosarcoma 98, 98
apoptosis 17
Argentinian-positive tumours 104
aromatase inhibitors 67
asbestos exposure 71, 119, 124
ascites 29, 36, 37
astrocytomas 102, 117
ataxia telangiectasia 24, 25
ATM gene 24, 25
autophagy 17
autosomal dominant cancer syndromes 24, 25
autosomal recessive cancer syndromes 24, 25
axillary mass 120, 125
bacterial infections 14, 15
bad news, breaking 27
Barrett’s oesophagus 73
basal cell carcinoma 101
BCR/ABL fusion gene 107
Bence Jones protein 113
bereavement 63
β2-microglobulin 38
bevacizumab 21, 48, 77, 83
biopsy 47
bladder cancer 92, 92–3
bleeding 29
Bloom syndrome 24
bone pain 29, 113
bone scans 43
bone tumours 98, 98–9
childhood 117
metastatic 36, 37, 123
bortezomib 113
bowel habit, change in 29
Bowen’s disease 101
brachytherapy 51
BRAF gene mutations 96, 101
Bragg peak 51
cancer
breast 38, 38, 38, 39, 81, 89, 91, 92, 92–3, 99–100, 100, 100, 101
breakdown 27
breast cancer 66–7
clinical features 66, 67
family history 118, 122
fertility preservation after 118, 122
screening 41
staging 66
breast examination 29, 66
breast-ovarian syndrome, hereditary 24, 67, 83
breastness
end of life care 62
on exertion 119, 124
Breslow thickness 100, 101
Burkitt-cell leukaemia 107
Burkitt’s lymphoma 110, 111
cachexia 31, 32, 34
cafeine 53
cancer anorexia and cachexia syndrome (CACS) 31, 63
carcinoid syndrome 30, 30, 105, 126
carcinoid tumours 105
carcinoma
childhood 117
of unknown primary (CUP) 64, 64, 64–5, 119, 124
carcinosarcoma, ovary 83
cardiac manifestations 32, 37
cardiac toxicity, therapy-related 53
cauda equina syndrome 34, 34
CDH1 gene 21, 75
cell cycle 18, 18–19
cloning 53
cell death, mechanisms 17
central nervous system (CNS) cancers 102, 102, 102–3
childhood cancers 116–17
lymphoma, primary 110–11
cervical cancer 86–7
cetuximab 77
cancers
chemicals, carcinogenic 14, 15
cervical intraepithelial neoplasia (CIN) 41, 87
cervical smear cytology 41, 87
cetuximab 77
cells, chemotherapy 48–9
chemoprevention 45
chemoreceptor trigger zone (CTZ) 55
cellular therapy 52, 52–3, 55
agents 48
alternating therapy 44, 45
assessment of toxicity 45
brain tumours 103
breast cancer 67
bladder cancer 92, 92–3
biopsy 47
bone pain 29, 113
bone scans 43
bone tumours 98, 98–9
childhood 117
metastatic 36, 37, 123
bortezomib 113
bowel habit, change in 29
Bowen’s disease 101
brachytherapy 51
BRAF gene mutations 96, 101
Bragg peak 51
breast examination 29, 66
breast-ovarian syndrome, hereditary 24, 67, 83
breastness
end of life care 62
on exertion 119, 124
Breslow thickness 100, 101
Burkitt-cell leukaemia 107
Burkitt’s lymphoma 110, 111
cancer anorexia and cachexia syndrome (CACS) 31, 63
carcinoid syndrome 30, 30, 105, 126
carcinoid tumours 105
carcinoma
childhood 117
of unknown primary (CUP) 64, 64, 64–5, 119, 124
carcinosarcoma, ovary 83
cardiac manifestations 32, 37
cardiac toxicity, therapy-related 53
cauda equina syndrome 34, 34
CDH1 gene 21
CDH1 gene 21, 75
cell cycle 18, 18–19
cloning 53
cell death, mechanisms 17
central nervous system (CNS) cancers 102, 102, 102–3
childhood cancers 116–17
lymphoma, primary 110–11
cervical cancer 86–7
cetuximab 77
cancer
chemicals, carcinogenic 14, 15
cervical intraepithelial neoplasia (CIN) 41, 87
cervical smear cytology 41, 87
cetuximab 77
chemoprevention 45
chemoreceptor trigger zone (CTZ) 55
cellular therapy 48–9
acute problems after 120, 125
adjuvant 44
adverse effects 52, 52–3, 55
agents 48
alternating therapy 44, 45
assessment of toxicity 45
brain tumours 103
breast cancer 67
carcinoma of unknown primary 65
cervical cancer 87
childhood cancer 115, 116, 117
colorectal cancer 77
dose dense 44, 45
drug resistance 49
endometrial cancer 85
gastric cancer 75
germ cell tumours 89
head and neck cancer 95
hepatobiliary cancer 81
high dose 44, 45
high temperature after 120–1, 126
low dose 44, 45
lung cancer 69
lymphoma 109, 111
myeloma 113
neoadjuvant 45
oesophageal cancer 73
ovarian cancer 83
palliative 44
pancreatic cancer 79
childhood cancers 114–17
epidemiology 114, 114, 115
treatment 115
chronic lymphoid leukaemia (CLL) 106, 107
chronic myeloid leukaemia (CML) 106, 107, 120, 124
clinical presentation cancer 28, 28–9
    carcinoma of unknown primary 64, 65
    clinical trials 58, 58–9, 61
    clinics, combined 61
    clubbing, finger 29
colorectal cancer 76–7
    co-analgesics 56, 57
colorectal cancer 76–7
    clinical features 76, 77
    liver metastases 123
    screening 41, 77
    staging 76, 77
colposcopy 87
common toxicity criteria (CTC) 45
communication 26, 26–7
Compton effect 50, 50
computed tomography (CT) 43
    incidental finding 118, 118–19, 123
confocal radiation therapy 51
confusion old man with 118, 122–3
    and thirst, in a smoker 120, 125
    and vomiting 120, 125
constipation 55, 57, 62
contact inhibition 19
    cough 62
    with swelling of face 118, 122
Cowden syndrome 24
Cushing’s syndrome 30, 30, 104
cyclin-dependent kinases (CDKs) 18, 19
cyclins 18, 19
cytogenetic analysis 13
cytokines 22, 23
cytology 13
depression 63
dermatomyositis 31
developed countries 10–11
developing countries 10–11
dexamethasone 35
    diabetes mellitus 79
diarrhoea 62
    facial flushing and 120, 126
diet 11, 14, 15
disease–patient relationship 26–7
domperidone 55
doubling time 49
    drug resistance 49
ductal carcinoma in situ (DCIS) 67
dysgerminoma 89
dysphagia 29, 73
    dyspnoea see breathlessness
eye early adverse effects, treatment 52
Eastern Cooperative Oncology Group (ECOG) performance status scale 12
    E-cadherin (cadherin-1) 16, 21, 23, 75
    economic burden, cancer 10, 10
    ectopic hormone production 30, 30
education professional 61
    public 11
electron beam radiation therapy 51
    embryonal tumours 115–16, 117
    emergencies
    metabolic 32, 32–3
    oncological 34, 34–5
    emotional patients, dealing with 27
    endocrine therapy see hormonal therapy
    end of life care 11, 62–3, 120, 125
    endometrial cancer 84, 84–5
    endometrial stromal sarcoma 98
    endothelial cells 23
    energy metabolism, reprogramming 23
    environmental determinants 14, 15
    ependymomas 102
    epidermal growth factor receptor (EGFR) 19, 77
    Epstein–Barr virus (EBV) 109, 111
    erbB family and ligands 18
    erythema gyratum 31
    erythrocyte sedimentation rate (ESR) 113
    ErbB family and ligands 18
    excision biopsy 47
facial flushing and diarrhoea 120, 126familial adenomatous polyposis (FAP) 24, 25, 77
    family history, cancer 118, 122
    Fanconi anaemia 24
    fertility preservation 118, 122
    fever 31
    after chemotherapy 120–1, 126
    fibrosarcoma 98
    fine-needle aspiration (FNA) 47
    FOLFIRINOX 79
    follicular lymphoma 110, 111
    follicular thyroid carcinoma 96
    fractures 80
gall bladder cancer 80
gamma knife 51
gastric cancer 74–5
    aetiology 11, 75
    clinical features 74, 75
    screening 41
    staging 74, 75
    gastrinoma 30, 105
    gastrointestinal manifestations, cancer 31, 32
    gastrointestinal stromal tumours (GIST) 98, 99
    gastrointestinal tract
    neuroendocrine tumours 104, 105
    toxicity, therapy-related 53
    gemcitabine 79
    gene mutations 16, 17, 24–5
    germ cell 24
    somatic 24–5
    genetics, cancer 24–5
    genome instability 17
    germ cell tumours (GCT) 88–9
    childhood 117
    extravaginal 88, 89, 117
    ovary 83, 88, 88, 117
    testicular 88, 88–9, 117
    germ line mutations 24
    gliomas 102, 103
    childhood 116, 117
    global burden of cancer 10, 10
    glucagonoma 30, 105
glycogenolytic, aerobic 23
    gonadal failure, premature 53
    Germin syndrome 24
growth, tumour 49
growth factor receptors 18, 19
    growth factors 18, 19
    growth fraction 49
    haematological cancers 106–13
    childhood 115
    haematological manifestations 31
    haloperidol 55
head and neck cancer 94, 94–5
Helicobacter pylori 11, 75
hepatic toxicity, therapy-related 53
hepatitis B virus (HBV) 11, 81
hepatitis C virus (HCV) 11, 81, 111
hepatobiliary cancer 80, 80–1
hepatoblastoma 116
hepatocellular carcinoma (HCC) 80, 81, 124
    hepateomegaly 119, 124
    HER2 19, 25, 67, 75
    hereditary cancer syndromes 24, 24, 25, 41
    hereditary non-polyposis colon cancer (HNPCC, Lynch syndrome) 24, 25, 77, 83
    hip pain 119, 123
    histopathology, tumour 13
    children 115
hormonal therapy breast cancer 67
    endometrial cancer 85
    prostate cancer 91
    hormone replacement therapy (HRT) 14, 15, 67
    hormones 14, 15
    cancer risk and 14, 15
    ectopic production 30, 30
    neuroendocrine tumours 104, 104, 105
    as tumour markers 39
    HPC1/HPC2 genes 24, 91
    human chorionic gonadotrophin (hCG) 38, 39, 89
    human papillomaviruses (HPV) 11, 87
    human T-cell lymphotrophic virus-1 (HTLV-1) 110, 111
    5-hydroxyindoleacetic acid (5-HIAA) 30
    5-hydroxytryptamine see serotonin
    hypercalcaemia 30, 32, 33, 125
    hypertrophic osteoarthropathy (HOA) 31
    hypomagnesaemia 32, 33
    hypoponeraemia 125
    imaging 42, 42–3
    imatinib 48, 99, 107
    immune evasion 22, 23
    incision biopsy 47
    infections 11, 14, 15
    infertility 53
    inflammatory pain 57
    inflammatory responses, tumour-associated 22, 23
    inherited cancer syndromes 24, 24, 25, 41
    inhibin 38, 39
    INK4 inhibitors 18
    insulinoma 30, 105
    intensity-modulated radiation therapy (IMRT) 51
    intercalating agents 48
pulmonary toxicity, therapy-related 53
punch biopsy 47
radiation exposure
carcinogenic effects 14, 15
sarcoma and 99
thyroid cancer and 96
radioisotope imaging 43
radiotherapy 50–1
adverse effects 52, 52–3, 55
brain tumours 103
breast cancer 67
cervical cancer 87
childhood cancer 115, 116
colorectal cancer 77
dermatological cancer 85
germ cell tumours 89
head and neck cancer 95
lung cancer 69
lymphoma 109, 111
mechanisms of action 50, 50–1
melanoma 101
mesothelioma 71
myeloma 113
pancreatic cancer 79
prostate cancer 91
thyroid cancer 97
types 51
randomisation 59
RAS mutations 19
RB1 gene 24, 116
reconstructive surgery 47
recurrent disease, surgical resection 47
Reed–Stemberg cells 109
remission rate 45
renal cancer 92, 92–3
renal manifestations 31, 32
reproductive system toxicity, therapy-related 53
residual disease 45
response evaluation criteria in solid tumours (RECIST) 44, 45
retinoblastoma 24, 116
retinoblastoma gene product (pRb) 18, 18, 19
RET proto-oncogene 24, 96
rhabdomyosarcoma 98, 98, 117
right upper quadrant pain 119, 123
rituximab 48, 111
sarcomas 98, 98, 98–9
childhood 117
screening 40, 40–1
second malignancies, cancer survivors 53
sedation, opioid-induced 57
seminoma 89, 117
sensitivity, screening test 40
sentinel node biopsy 43, 47
sepsis, neutropenic 34, 35, 126
serotonin (5-HT) 30, 104, 105
serotonin antagonists 55
sex cord tumours, ovary 83
Sister Mary Joseph nodules 83
skin cancer 100, 100–1
skin manifestations, cancer 29, 31
skin metastasis 37
skin toxicity, therapy-related 53
small cell lung cancer (SCLC) 69
smoking 11, 14, 15, 69
soft tissue sarcomas 98, 99
childhood 117
somatic mutations 24–5
somatic pain 57
somatostatin analogues 105
somatostatinoma 105
specificity, screening test 40
spinal cord compression 34, 34, 35, 122
spinal cord tumours 102, 102, 103
spinal cord compression 34, 34, 35, 122
spirituality 63
squamous cell carcinoma
lung 69
oesophagus 73
skin 101
of unknown primary (CUP) 119, 124
squamous cell carcinoma-associated antigen (SCCA) 38, 39
stage, tumour 13
staging 47
stem cell transplantation (SCT) 107, 111, 113
sterotactic radiosurgery 51
steroid therapy 35
sun exposure 15, 101
sunitinib 21
superior vena cava (SVC) obstruction 34, 35, 69, 122
surgical oncology 46, 46–7
surgical resection
bladder and renal cancer 93
bone cancer and sarcoma 99
brain tumours 103
breast cancer 67
cervical cancer 87
childhood cancers 116, 117
colorectal cancer 77
dermatological cancer 85
gastric cancer 75
germ cell tumours 89
head and neck cancer 95
hepatobiliary cancer 81
lung cancer 69
mesothelioma 71
oesophageal cancer 73
ovarian cancer 83
pancreatic cancer 79
prostate cancer 91
skin cancer 100, 101
thyroid cancer 97
survival rate, overall 45
syndrome of inappropriate antidiuresis (SIAD) 32, 33, 125
ttoscutic cancer 98
tamoxifen 67
taxanes 48
team, multidisciplinary (MDT) 60, 60–1
teenger and young adult (TYA) oncology 115
telomerase 19
teratogenesis 53
terminal care 62, 63, 120, 125
testicular germ cell tumours 88, 88–9, 117
thyroglobulin 38, 97
thyroid cancer 96, 96–7, 117
thyroid nodules 97
tobacco use 11, 15
topoisomerase I/II inhibitors 48
TP53 gene 16, 17, 19, 20, 24
transitional cell cancer (TCC) 92, 93
transurethral resection of bladder tumour (TURBT) 93
trazodone 48, 67, 75
treatment
access to 11
adverse effects 52, 52–3
approach 44–5
childhood cancers 115
goals 44–5
response assessment 44, 44, 45
surgical 47
trousseau’s syndrome 31
tubulin binders 48
tumour lysis syndrome 32, 33, 125
tumour markers 38, 38–9, 105
tumour necrosis factor (TNF) 22
tumours
angiogenesis 20, 21
grade 13
growth 49
invasion and metastasis 20, 21
multistep progression 16, 17
nomenclature 12, 13
stage 13
see also cancer
tumour suppressor genes 19, 25
two hit hypothesis, Knudson’s 25
tylosis, hereditary 73
ultrasound imaging 43
ultraviolet (UV) radiation 14, 15, 101
urothelial toxicity, therapy-related 53
vascular endothelial growth factor (VEGF) 20, 21, 77
venurafibib 101
vinca alkaloids 48
VIPoma 30, 105
viral infections 14, 15
Vichow’s node 73, 75
visceral pain 57
vomiting see nausea and vomiting
von Hippel–Lindau syndrome 24, 92, 103
weight loss 29, 31, 119, 124
Whipple’s procedure 81
Wilms’ tumour 24, 116
World Cancer Declaration 10
World Health Organization (WHO) analogues pain ladder 56, 37
screening criteria 40, 40
xeroderma pigmentosa 24
X-rays, plain film 42, 43
younger patients, communicating with 27